Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;23(6):408-16.
doi: 10.1002/jcla.20342.

IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis

Affiliations

IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis

Erasmo Martínez-Cordero et al. J Clin Lab Anal. 2009.

Abstract

Background: Anti-DNA topoisomerase I (anti-topo I) antibodies have been broadly studied in systemic sclerosis (SSc). The use of different native and molecularly cloned antigens has shown a predominant IgG response, and a variable frequency of positive IgM and IgA tests. We report herein the serological findings of SSc using a recombinant topo I obtained through a standard bacterial system.

Methods: Anti-topo I antibodies were studied in 45 SSc patients and 85 healthy controls through ELISA and western blot. Escherichia coli XL1-blue strain and pT7-7 vector were used to amplify a DNA topo I cDNA clone, and to obtain the recombinant polypeptide. The latter was purified by affinity chromatography, and the enzymatic and antigenic properties were evaluated through specific tests. A native antigen was included for comparison.

Results: The SSc group disclosed positive IgM (20%), IgG (86.6%), and IgA (26.6%) anti-topo I tests with the recombinant polypeptide, and a purified calf thymus antigen yielded similar results. IgG autoantibodies were frequently associated with skin involvement, esophageal dysfunction, and restrictive lung disease. The recombinant protein showed a molecular weight of 86.6 kDa, a positive topo I activity using a supercoiled pBR322 DNA relaxation test, and its carboxyl terminus region was recognized by specific antibodies.

Conclusion: This report confirms that different immunoglobulin classes with anti-topo I activity may occur in SSc. IgG was the predominant serological feature with both, the recombinant and native antigens. The study also demonstrates the association between high levels of these autoantibodies and some clinical manifestations of SSc.

PubMed Disclaimer

References

    1. Medsger TA Jr. Systemic sclerosis (scleroderma), localized scleroderma, eosinophilic fasciitis, and calcinosis In: McCarty DJ, editor. Arthritis and Allied Conditions. Philadelphia: Lea & Febiger; 1989. p 1118–1165.
    1. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl‐70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514–10522. - PubMed
    1. Steen VD, Powell DL, Medsger TA Jr. Clinical correlation and prognosis based on serum autoantibodies in patients with systemic sclerosis. Intern Rev Immunol 1995;12:145–157. - PubMed
    1. Weiner ES, Earshaw WC, Senecal JL, et al. Clinical association of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988;31:378–385. - PubMed
    1. Rothfield N, Kurtzman S, Vazques‐Abad D, et al. Association of antitopoisomerase l with cancer. Arthritis Rheum 1992;35:724. - PubMed

Publication types